Full Year 2026 Remus Pharmaceuticals Ltd Earnings Call Transcript

May 21, 2026 / 08:30 AM GMT

Release Date Price: ₹804.95 (-5.88%)

Transcript

Key Points

Positve

Remus Pharmaceuticals Ltd (NSE:REMUS) reported a 14% year-on-year growth in revenue from operations for the second half of FY26.
The company achieved a net profit increase of 19% year-on-year, with a PAT margin of 96.96%.
Remus Pharmaceuticals Ltd expanded its global footprint, operating in over 40 countries, with a strong presence in Latin America.
The B2C business segment saw significant growth, increasing its contribution from 4% to 14% of total revenue.
The company successfully cleared the Peru Digimed audit, enhancing its regulatory credibility and supporting future expansion in Latin America.

Negative

The company's margins dipped slightly in FY26 compared to FY25, primarily due to increased R&D investments.
Geopolitical situations caused delays in product launches, impacting the expected growth in the B2C segment.
The operating cash flow remained weak despite strong profit growth, largely due to working capital investments in the US subsidiary.
The company faces challenges in managing Forex volatility and receivable risks in markets like Venezuela and Bolivia.
There is a dependency on external manufacturing partners, with 34 approved manufacturers, which could pose supply chain risks.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

REMP.NS - Remus Pharmaceuticals Ltd
Full Year 2026 Remus Pharmaceuticals Ltd Earnings Call
May 21, 2026 / 08:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and Gentlemen, good day and welcome to the Remus Pharmaceuticals Limited's H2FY26 Earnings Conference Call.

As a reminder, all participant nines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes.

Should you need assistance during the conference call, please signal an operator by pressing then 0 on your touchtone phone.

I now hand the conference call over to Ms. Parvangi Jain from Valorum Advisors.

Thank you and over to you.

--------------------------------------------------------------------------------
Unidentified_2 [2]
-------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.